Key Takeaways OPK posted Q4 loss of 4 cents, beating estimates as $148.5M revenue topped estimates despite 19% drop.OPK's Diagnostics revenue fell 30.5% on lower test volume after BioReference asset sale.OPK guides 2026 revenues of $530M-$560M, with Q1 outlook of $125M-$140M.OPKO Health, Inc. (OPK) delivered a loss per share of 4 cents in the fourth quarter of 2025, against an earnings per share of a cent in the prior-year quarter. Earnings beat the Zacks Consensus Estimate of a loss of 7 cents per share by ...

MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biophar ...

Core Insights - OPKO Health reported a revenue of $148.5 million for the quarter ended December 2025, reflecting a decline of 19.1% year-over-year, but exceeded the Zacks Consensus Estimate by 7.56% [1] - The company's EPS was -$0.04, a decrease from $0.01 in the same quarter last year, but surpassed the consensus estimate of -$0.07 by 39.39% [1] Revenue Breakdown - Revenue from services was $71.1 million, slightly below the average estimate of $72.37 million, marking a year-over-year decline of 31% [4] - Revenue from the transfer of intellectual property and other sources was $33.7 million, exceeding the average estimate of $24.39 million, with a year-over-year decrease of 21.8% [4] - Revenue from products reached $43.7 million, surpassing the estimated $41.31 million, and showed a year-over-year increase of 16.8% [4] Stock Performance - OPKO Health's shares have returned -7.8% over the past month, contrasting with a +0.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

OPKO Health (OPK) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +39.39%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.02 per share when it actually produced earnings of $0.03, delivering a s ...

OPKO Health (NasdaqGS:OPK) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAdam Logal - SVP and CFOElias Zerhouni - Vice Chairman and PresidentGary Nabel - CIOPhillip Frost - Chairman and CEOYvonne Briggs - Director of Investor RelationsNone - Company RepresentativeConference Call ParticipantsBrian Cheng - Executive Director and Senior Biotech AnalystEdward Tenthoff - Managing Director and Senior Research AnalystMaury Raycroft - Equity Research AnalystYale Jen - Senior Biotech Analys ...

OPKO Health (NasdaqGS:OPK) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAdam Logal - SVP and CFOElias Zerhouni - Vice Chairman and PresidentGary Nabel - CIOPhillip Frost - Chairman and CEOYvonne Briggs - Director of Investor RelationsNone - Company RepresentativeNone - Company RepresentativeConference Call ParticipantsBrian Cheng - Executive Director and Senior Biotech AnalystEdward Tenthoff - Managing Director and Senior Research AnalystYale Jen - Senior Biotech AnalystOperatorHe ...

OPKO Health (NasdaqGS:OPK) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker5Hello and welcome to the OPKO Health Fourth Quarter 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask your question, you may press Star then one on your telephone keypad. To withdraw your question, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 Miami, FL 33137 (Address of Principal Executive Offices) (Zip Code) (305) 575-4100 (Registrant's Telephone N ...

MIAMI, February 26, 2026 – OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: • Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regene ...

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new p ...